Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology | MicrobiomeTrials← Back to trialsNCT04264975
Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2018-06-04Est. Completion: 2027-04-30
Enrollment target: 60 participants Locations- Asan Medical Center, Seoul, Seoul, South Korea
Other microbiome trials you might be interested in
Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to …
New Haven, United StatesEst. completion May 2029
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoidCarcinoid TumorPancreatic NET
Solid Tumor
Somatostatin Receptor
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize …
Iowa City, United StatesEst. completion Feb 2027
Non-small Cell Lung Cancer
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or …
Duarte, United StatesEst. completion Nov 30, 2026